BiotechTube

OnabotulinumtoxinA + KYBELLA

ApprovedActive
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Facial Contouring

Conditions

Facial Contouring

Trial Timeline

Jan 16, 2025 → Mar 1, 2026

NCT ID
NCT06783621

About OnabotulinumtoxinA + KYBELLA

OnabotulinumtoxinA + KYBELLA is a approved stage product being developed by AbbVie for Facial Contouring. The current trial status is active. This product is registered under clinical trial identifier NCT06783621. Target conditions include Facial Contouring.

What happened to similar drugs?

3 of 7 similar drugs in Facial Contouring were approved

Approved (3) Terminated (0) Active (4)
✅BOTOXAbbVieApproved
✅BOTOX®/VISTABEL®AbbVieApproved
✅Erenumab Prefilled SyringeAmgenApproved
🔄EMLA CreamSanofiPhase 3
🔄Botulinum toxin type AIpsenPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06783621ApprovedActive

Competing Products

13 competing products in Facial Contouring

See all competitors
ProductCompanyStageHype Score
BOTOXAbbVieApproved
43
BOTOX®/VISTABEL®AbbVieApproved
43
Erenumab Prefilled SyringeAmgenApproved
43
RapamunePfizerPhase 1
29
EMLA CreamSanofiPhase 3
40
Diflucortolone valerate (BAY866146)BayerPre-clinical
23
Botulinum toxin type AIpsenPhase 3
37
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
IPN59011 + Azzalure + PlaceboIpsenPhase 1
18
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)BaxterPhase 2
32
Metyrosine + PlaceboBausch HealthPhase 2
21
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30